Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer

The company is primarily engaged in the discovery and development of immuno-oncology products, aiming to harness the body’s immune system to fight against various types of tumors. Corvus leverages its expertise in biologic compounds to create targeted treatments that enhance immune response while minimizing side effects. Through its ongoing research and clinical trials, the company seeks to provide new options for patients with unmet medical needs in oncology.